| dc.contributor |
Massachusetts Institute of Technology. Department of Chemical Engineering |
|
| dc.contributor |
Massachusetts Institute of Technology. Institute for Medical Engineering & Science |
|
| dc.contributor |
Harvard University--MIT Division of Health Sciences and Technology |
|
| dc.contributor |
Koch Institute for Integrative Cancer Research at MIT |
|
| dc.creator |
Aijaz, Ayesha |
|
| dc.creator |
Li, Matthew |
|
| dc.creator |
Smith, David |
|
| dc.creator |
Khong, Danika |
|
| dc.creator |
LeBlon, Courtney |
|
| dc.creator |
Olabisi, Ronke M. |
|
| dc.creator |
Libutti, Steven |
|
| dc.creator |
Tischfield, Jay |
|
| dc.creator |
Maus, Marcela V. |
|
| dc.creator |
Deans, Robert |
|
| dc.creator |
Barcia, Rita N. |
|
| dc.creator |
Anderson, Daniel Griffith |
|
| dc.creator |
Ritz, Jerome |
|
| dc.creator |
Preti, Robert |
|
| dc.creator |
Parekkadan, Biju |
|
| dc.creator |
Fenton, Owen Shea |
|
| dc.date |
2019-08-09T19:59:11Z |
|
| dc.date |
2019-08-09T19:59:11Z |
|
| dc.date |
2018-06 |
|
| dc.date |
2017-07 |
|
| dc.date |
2019-08-09T14:00:45Z |
|
| dc.date.accessioned |
2023-03-01T18:09:48Z |
|
| dc.date.available |
2023-03-01T18:09:48Z |
|
| dc.identifier |
2157-846X |
|
| dc.identifier |
https://hdl.handle.net/1721.1/121979 |
|
| dc.identifier |
Aijaz, Ayesha et al. "Biomanufacturing for clinically advanced cell therapies." Nature Biomedical Engineering 2, 6 (June 2018): 362–376 © 2018 The Author(s) |
|
| dc.identifier.uri |
http://localhost:8080/xmlui/handle/CUHPOERS/278988 |
|
| dc.description |
The achievements of cell-based therapeutics have galvanized efforts to bring cell therapies to the market. To address the demands of the clinical and eventual commercial-scale production of cells, and with the increasing generation of large clinical datasets from chimeric antigen receptor T-cell immunotherapy, from transplants of engineered haematopoietic stem cells and from other promising cell therapies, an emphasis on biomanufacturing requirements becomes necessary. Robust infrastructure should address current limitations in cell harvesting, expansion, manipulation, purification, preservation and formulation, ultimately leading to successful therapy administration to patients at an acceptable cost. In this Review, we highlight case examples of cutting-edge bioprocessing technologies that improve biomanufacturing efficiency for cell therapies approaching clinical use. |
|
| dc.format |
application/pdf |
|
| dc.language |
en |
|
| dc.publisher |
Springer Science and Business Media LLC |
|
| dc.relation |
http://dx.doi.org/10.1038/s41551-018-0246-6 |
|
| dc.relation |
Nature Biomedical Engineering |
|
| dc.rights |
Creative Commons Attribution-Noncommercial-Share Alike |
|
| dc.rights |
http://creativecommons.org/licenses/by-nc-sa/4.0/ |
|
| dc.source |
PMC |
|
| dc.title |
Biomanufacturing for clinically advanced cell therapies |
|
| dc.type |
Article |
|
| dc.type |
http://purl.org/eprint/type/JournalArticle |
|